Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.00
C$0.15
C$1.23
C$15.64M0.19135,475 shs167,044 shs
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$0.26
-3.8%
C$0.26
C$0.15
C$0.53
C$52.28MN/A644,760 shs384,329 shs
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$10.70
$10.70
$3.95
$11.35
$292.42M2.38327,575 shs54 shs
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$6.47
$6.47
$5.73
$8.75
$644.66M0.01N/AN/A
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00%0.00%0.00%0.00%0.00%
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00%0.00%0.00%0.00%0.00%
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.00
N/AN/AN/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
0.00
N/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.00
N/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$9.71M0.00N/A0.61C$0.49 per share0.00
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
C$13.02M4.02C$0.33 per share0.78C$0.40 per share0.64
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$937.80M0.31$1.97 per share5.43$3.40 per share3.15
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
$448.27M1.44$0.17 per share38.95$120.83 per share0.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
-C$18.24M-C$0.35N/AN/AN/AN/A-52.72%-19.13%N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/A-C$0.70N/AN/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
$48.50M$1.776.05N/A5.17%66.00%15.67%N/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
-$99.92MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
C$0.05N/AN/AN/A N/A
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
N/AN/AN/AN/AN/A
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
N/AN/AN/AN/AN/A
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/AN/AN/A

Latest ATE, SVA, EMH, and HBP Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/29/2025
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
--$55.007/8/20255/23/20257/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
0.29
10.06
9.58
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
35.45
2.97
2.61
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
0.75
2.05
0.95
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Antibe Therapeutics Inc. stock logo
ATE
Antibe Therapeutics
1153.01 millionN/ANot Optionable
Emerald Health Therapeutics, Inc. stock logo
EMH
Emerald Health Therapeutics
161205.03 millionN/ANot Optionable
Huttig Building Products, Inc. stock logo
HBP
Huttig Building Products
1,10027.33 million24.34 millionOptionable
Sinovac Biotech, Ltd. stock logo
SVA
Sinovac Biotech
3,26199.64 million86.89 millionOptionable

Recent News About These Companies

Sinovac Controlling Investors Ordered to Amend Disclosures

Top Headlines

View All Headlines
Antibe Therapeutics stock logo

Antibe Therapeutics TSE:ATE

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Emerald Health Therapeutics stock logo

Emerald Health Therapeutics CVE:EMH

C$0.26 -0.01 (-3.77%)
As of 04/26/2021

Emerald Health Therapeutics, Inc., together with its subsidiaries, produces and sells medical cannabis for medical purpose in Canada. The company is also involved in developing natural health products. It offers dried cannabis strains, pre-rolls, and cannabis oil products to its medical patients. The company was formerly known as T-Bird Pharma Inc. and changed its name to Emerald Health Therapeutics, Inc. in June 2015. Emerald Health Therapeutics, Inc. is headquartered in Vancouver, Canada.

Huttig Building Products stock logo

Huttig Building Products NASDAQ:HBP

Huttig Building Products, Inc., together with its subsidiaries, distributes millwork, building materials, and wood products for new residential construction, in-home improvement, remodeling, and repair works in the United States. The company offers various millwork products, including exterior and interior doors, pre-hung and factory finished door units, windows, patio doors, mouldings, frames, stair parts, and columns under the Therma-Tru, Masonite, Woodgrain, HB&G, Simpson Door, Final Frame, BrasPine, Arauco, Windsor Windows, and Rogue Valley Door brands. It also provides general building products, such as fasteners and connectors, roofing, siding, insulation, flashing, housewrap, decking, railings, and other miscellaneous building products under the Huttig-Grip, Louisiana-Pacific, Simpson Strong-Tie, TimberTech, AZEK, RDI, GAF Roofing, Maibec, Knauf, GCP Technologies, Fiberon, Alpha Protech, MFM, Lomanco, and Fortifiber brands. In addition, the company offers wood products comprising engineered wood products used in floor systems, wood panels, and lumber; and value-added services, such as floor system take-offs, cut-to-length packages and just-in-time, and cross-dock delivery under the Louisiana-Pacific and Rosboro brands. It markets and sells its products through a network of 25 wholesale distribution centers serving approximately 41 states to building materials dealers, national buying groups, home centers, and industrial users comprising makers of manufactured homes. Huttig Building Products, Inc. was founded in 1865 and is headquartered in St. Louis, Missouri.

Sinovac Biotech stock logo

Sinovac Biotech NASDAQ:SVA

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.